- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: How to Improve Perception Hurdles to Biosimilar Adoption
This is part 1 of a series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced that 10 research projects have been chosen to receive funding to focus on innovative ways to improve biosimilar adoption in the oncology space.
For this 3-part series of Not So Different, The Center for Biosimilars® has chosen projects that relate to improving perception of biosimilars, choice of biosimilars, and payer preferences for biosimilars.
In this first part, we spoke with Claire Saxton, vice president of education at Cancer Support Community, a worldwide patient and family advocacy organization that provides financial support and navigation services. Saxton discussed how her project titled “Frankly Speaking About Cancer: Biosimilars—Researching Oncology Patient and Caregiver Perceptions” will help address the current perception issues surrounding biosimilars.
For more on biosimilar perception, click here.
For more on NCCN’s biosimilar work, click here.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
